


Darbepoetin Exhibits **Greater Consistency** Over Time.



Efficacy of darbepoetin alfa vs. epoetin



*p<0.001 (compared to week 0).

Epoetin 6000 IU QTIW therapy; Darbepoetin 60 μg QW therapy.

QTIW: Three times per week; QW: Once weekly.

Epoetin alfa fails

- To induce the desired Hb elevation
- To stop fluctuation in Hb levels

Darbepoetin alfa

- Increases Hb levels
- Maintains its levels within recommended target range
- Has less variability over time

Which ESA do you prefer to use for correcting Hb levels in CKD patients?



Long-acting ESA (darbepoetin alfa)





Short-acting ESA (epoetin alfa)



Change for Better...Change to



Abbreviations

CKD: Chronic kidney disease; ESA:Erythropoietin-stimulating agent; Hb: Hemoglobin.

Reference: Alkatheri A, Albekairy A, Al-Rajhi Y, et al. Comparison of the effectiveness of equal doses of short and long-acting erythrocyte stimulating agents for managing anemia in chronic kidney disease adult patients. Int J Med Res Health Sci. 2016;5(12):335–342.

LMRC Code: GGI-CO-A1-AQS-DCVN-BANNERS-I23-0349

For the use of a Registered Medical Practitioner, Hospital or Laboratory only.

All content including: text, images, audio, or other formats were created for medical educational purposes only. Offerings for continuing education are clearly identified and the appropriate target audience is identified. This communication is restricted for the use of HCPs and must not be shared in public domain. The opinions expressed in this video are solely the views of the speaker. The presentation may contain off label usage of drug(s) aimed at educational purpose only. Dr. Reddy's Laboratories Ltd including but not limited its Affiliates strictly does not recommend any off label usage of its marketing products. Prior to treatment kindly refer to the latest prescribing information approved by the local authorities. No part of this content may be used, reproduced, transmitted or stored in any form without the written permission of Dr. Reddy's.